First in Human Study for Safety and Tolerability of AL003.

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 29, 2019

Primary Completion Date

May 6, 2021

Study Completion Date

May 6, 2021

Conditions
HealthyAlzheimer Disease
Interventions
BIOLOGICAL

AL003

"Single-doses of AL003 in dose-escalating cohorts~Multiple doses of AL003 in a single cohort"

OTHER

Saline Solution

Saline Solution will be administered as a single infusion for each dose escalation cohort in a ratio of 6 active and 2 placebo and as multiple infusions in the single cohort in a ratio of 10 active and 2 placebo

Trial Locations (6)

10032

Columbia University, New York

32159

Charter Research, Lady Lake

32162

Synexus AES, The Villages

32806

PPD Clinical Research Unit, Orlando

33445

Brain Matters Research, Delray Beach

Unknown

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alector Inc.

INDUSTRY